Trial tests bedtime pill for preschoolers with ADHD
NCT ID NCT06431256
Summary
This study aimed to test the effectiveness and safety of a long-acting ADHD medication, HLD200, given in the evening to children aged 4 to 5 years. The goal was to see if taking the pill at night could help control ADHD symptoms during the following day. The trial was a Phase 3 study but was terminated early, enrolling only 26 of a planned 168 children.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION-DEFICIT/HYPERACTIVITY DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advanced Research Center, Inc.
Anaheim, California, 92805, United States
-
Alivation Research, LLC
Lincoln, Nebraska, 68526, United States
-
CenExel iResearch, LLC
Decatur, Georgia, 30030, United States
-
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, 32256, United States
-
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, 32801, United States
-
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, 38119, United States
-
Coastal Pediatric Research
Summerville, South Carolina, 29486, United States
-
DelRicht Research
New Orleans, Louisiana, 70115, United States
-
Harmonex, Inc.
Dothan, Alabama, 36303, United States
-
Midwest Research Group
Saint Charles, Missouri, 63304, United States
-
South Florida Research
Miami Springs, Florida, 33166, United States
-
University of Cincinnati Health
Cincinnati, Ohio, 45219, United States
-
Vector Clinical Trials
Las Vegas, Nevada, 89128, United States
Conditions
Explore the condition pages connected to this study.